Reduced Let-7f in Bone Marrow-Derived Mesenchymal Stem Cells Triggers Treg/Th17 Imbalance in Patients With Systemic Lupus Erythematosus

Geng, Linyu; Tang, Xiaojun; Wang, Shiying; Sun, Yue; Wang, Dandan; Tsao, Betty P.; Feng, Xuebing; Sun, Lingyun

doi:10.3389/fimmu.2020.00233

Cited by 32 publications

(24 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Mesenchymal stem cells (MSCs) have been widely used in the clinical setting, not only for autoimmune diseases [ 9 , 10 ] but also for infectious diseases [ 11 – 13 ], and their safety and effectiveness have been well elucidated. Umbilical cord mesenchymal stem cells (hUC-MSCs), a kind of MSC, can be easily obtained and expanded in vitro.…”

Section: Introductionmentioning

confidence: 99%

Treatment of severe COVID-19 with human umbilical cord mesenchymal stem cells

et al. 2020

View full text Add to dashboard Cite

Background: COVID-19 is a highly infectious respiratory disease. No therapeutics have yet been proven effective for treating severe COVID-19. Objectives: To determine whether human umbilical cord mesenchymal stem cell infusion may be effective and safe for the treatment of severe COVID-19. Methods: Patients with severe COVID-19 were randomly divided into 2 groups: the standard treatment group and the standard treatment plus hUC-MSC infusion group. The incidence of progression from severe to critical illness, 28-day mortality, clinical symptom improvement, time to clinical symptom improvement, hematologic indicators including C-reactive protein, lymphocyte number, and interleukin 6, and imaging changes were observed and compared between the two groups. Measurements and main results: The incidence of progression from severe to critical illness and the 28-day mortality rate were 0 in the hUC-MSC treatment group, while 4 patients in the control group deteriorated to critical condition and received invasive ventilation; 3 of them died, and the 28-day mortality rate was 10.34%. In the hUC-MSC treatment group, the time to clinical improvement was shorter than that in the control group. Clinical symptoms of weakness and fatigue, shortness of breath, and low oxygen saturation obviously improved beginning on the third day of stem cell infusion and reached a significant difference on day 7. CRP and IL-6 levels were significantly lower from day 3 of infusion, the time for the lymphocyte count to return to the normal range was significantly faster, and lung inflammation absorption was significantly shorter on CT imaging in the hUC-MSC group than in the control group. Conclusions: Intravenous transplantation of hUC-MSCs is a safe and effective method that can be considered a salvage and priority treatment option for severe COVID-19.

show abstract

Section: Introductionmentioning

confidence: 99%

Treatment of severe COVID-19 with human umbilical cord mesenchymal stem cells

et al. 2020

View full text Add to dashboard Cite

show abstract

“…Mesenchymal stem cells (MSCs) have been widely used for solution of clinical issues, not only just in autoimmune diseases [8,9], but also in infectious diseases [10][11][12], and the safety and effectiveness have been well elucidated. Umbilical cord mesenchymal stem cells (hUC-MSCs), as one kind of MSCs, can be easily obtained and expansion in vitro.…”

Section: Introductionmentioning

confidence: 99%

Treatment of Severe COVID-19 with human Umbilical Cord Mesenchymal Stem Cells

Shu¹,

Niu

et al. 2020

Preprint

109

View full text Add to dashboard Cite

Background COVID-19 is a highly infectious respiratory disease. No effective therapeutics have yet been proved for treating of severe COVID-19. Objectives To determine whether human Umbilical Cord Mesenchymal Stem Cells infusion may be effectiveness and safety in the treatment of severe COVID-19. Methods The severe COVID-19 randomly divided into 2 groups, standard treatment group and standard treatment plus hUC-MSCs infusion group. The incidence of severe patients aggravated to critically illness, 28-day mortality, clinical symptoms improvement, time to clinical symptoms improvement, hematologic indicators including C-reaction protein, lymphocyte number, interleukin 6 and imaging changes were observed and compared between two groups. Measurements and Main Results The incidence of severe patients aggravated to critically illness and 28-day mortality were 0 in hUC-MSCs treatment group, while 4 patients in control group were deteriorated to critical illness and been used invasive ventilation, 3 of them died, and 28-day mortality was 10.34%. In hUC-MSCs treatment group, the time to clinical improvement was shorter, clinical symptoms of weakness and fatigue, shortness of breath, and low oxygen saturation had improved obviously began the third day of stem cells infusion, and reached the significant difference on the day 7, CRP and IL-6 were significantly decreased from day 3 of infusion, the time for lymphocyte count returned to normal range was significant faster, and lung inflammation absorption was significantly shorter from CT imaging. Conclusions Intravenous transplantation of hUC-MSCs is a safe and effective way that can be considered as salvage and priority choice in the treatment of severe COVID-19.

show abstract

“…T-cell immunosuppressive effects of MSCs in controlling Th17 and Th1 depend on the doses of MSC introduction to the inflammatory milieu in addition to the presence of other immune cells and the immune cells released soluble factor [17]. Other studies revealed that early MSCs administration into the autoimmune developing animal model might ameliorate those severity diseases, whereas later administration did not improve the imbalance of Th17 cells [18], [19]. To explore the potency of MSCs in controlling Th17 and Th1, we used in vitro model of the coculture of MSCs and PBMCs from SLE patients for 72 h of incubation with several doses.…”

Section: Discussionmentioning

confidence: 99%

The Normal Ratio of Th17 and Th1 Post-mesenchymal Stem Cells Coculture with PBMCs of Systemic Lupus Erythematosus Patients

Kustiyah

Putra²,

Nasihun

et al. 2021

Open Access Maced J Med Sci

View full text Add to dashboard Cite

BACKGROUND: Systemic lupus erythematosus (SLE) is a chronic autoimmune disease characterized by altered T-cell population homeostasis, including Th1 and Th17 populations. Mesenchymal stem cell (MSC)-induced i-Treg in SLE milieu can suppress Th17 cell populations; however, Th1 cell population status as a response to the Th17 decrease remains unclear. Therefore, improving SLE flare by suppressing Th17 and constantly controlling Th1 under normal level through MSCs administration is crucial. AIM: This study aimed to investigate the role of MSCs in suppressing Th17 cell populations and controlling Th1 to a normal level by in vitro coculturing MSCs with PBMC from SLE patients.. METHODS: This study used a post-test control group design. MSCs were obtained from human umbilical cord blood and characterized according to their surface antigen expression and multilineage differentiation capacities. PBMCs isolated from SLE patients were divided into five groups: Sham, control, and three treatment groups. The treatment groups were treated by coculturing MSCs to PBMCs with a ratio of 1:10, 1:25, and 1:40 for 72 h incubation. Th1 and Th17 cells were analyzed by flow cytometry. RESULTS: This study showed that there was no significance difference of the percentages of Th1 cells on all treatment groups. On the other hand, the percentages of Th17 were significantly decreased on T1 group. Interestingly, there was also significant decrease of Th1-like Th17 cells population on T1 group. CONCLUSIONS: MSCs may suppress Th17 and control Th1 to a normal level by in vitro coculturing MSCs with PBMC from SLE.

show abstract

Reduced Let-7f in Bone Marrow-Derived Mesenchymal Stem Cells Triggers Treg/Th17 Imbalance in Patients With Systemic Lupus Erythematosus

Cited by 32 publications

References 36 publications

Treatment of severe COVID-19 with human umbilical cord mesenchymal stem cells

Treatment of severe COVID-19 with human umbilical cord mesenchymal stem cells

Treatment of Severe COVID-19 with human Umbilical Cord Mesenchymal Stem Cells

The Normal Ratio of Th17 and Th1 Post-mesenchymal Stem Cells Coculture with PBMCs of Systemic Lupus Erythematosus Patients

Contact Info

Product

Resources

About